Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Withdrawn
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. Evaluate the efficacy of letrozole to increase the duration of progression-free survival
(defined as time to earliest occurrence of local or distant recurrence or clinically
significant elevation in CA-125) when used as adjuvant treatment after completion of primary
surgery and first line platinum containing chemotherapy in patients with optimally debulked
(< 1 cm residual disease) stage IIA-IIIC ovarian, fallopian tube, or primary peritoneal
cancer.
Secondary Objective:
1. Observe the incidence of local and distant recurrences.